What is the Purpose of this Study?
To enhance the understanding of the variability, progression, and natural history of Gaucher disease with the ultimate goal of better guiding and assessing therapeutic interventions; To provide the Gaucher medical community with recommendations for monitoring patients and to provide reports on patient outcomes to help optimize patient care; and To evaluate the long-term effectiveness of Cerezyme.
Eligibility
- ICGG Gaucher Registry
- All patients with a confirmed diagnosis of Gaucher disease are eligible for inclusion in the Registry. Confirmed diagnosis is defined as a documented β-glucocerebrosidase deficiency and/or mutation in the β-glucocerebrosidase gene.
- For all patients, appropriate patient authorization will be obtained.
Where can I participate?
Cedars-Sinai Cancer at Beverly Hills (THO)
More about this Clinical Trial
What is the full name of this clinical trial?
International Collaborative Gaucher Group Gaucher Registry